Cellular drug resistance in childhood acute myeloid leukemia - A mini-review with emphasis on cell culture assays

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 415-421

  Kaspers, G J L ^a   Zwaan, Ch M ^a   Pieters, R ^a   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Anthracyclines; Childhood; Cytarabine; Drug resistance; Review

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CELL CULTURE; CHILD; DRUG SCREENING; HUMAN; MULTIDRUG RESISTANCE; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CHILD; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOCYTIC, ACUTE; TUMOR CELLS, CULTURED;

EID: 0032605141     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_44     Document Type: Article

References (32)

1. Creutzig U, Rittter J, Schellong G. Identification of two risk groups in childhood acute myelogeneous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990, 75: 1932-1940
2. Pui Ch. Childhood leukemias. New Engl J Med 1995, 332: 1618-1630
3. Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leakemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myedloid leukaemia: results of the United Kingdom Medical research Council's 10th AML trial. Br J Haematol 1998, 101: 130-140
4. Pieters R, Kaspers GJL, Veerman AJP. Drug sensitivity culture assays in childhood leukemia: A review of the results and applications. Int J Pediatr Hematol Oncol 1997, 4: 531-541
5. Preisler HD, Gopal V. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 1994, 18: 149-160
6. Bosanquet AG. Short-term in vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations of test results with both patient response and survival. Trends in Experimental and Clinical Medicine 1994, 4: 179-195
7. Veerman AJP, Pieters R. Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 1990, 74: 381-384
8. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treatm Rep 1986, 70: 1283-1295
9. Kaspers GJL, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, De Waal FC, Van Wering ER, Veerman AJP. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A preliminary report. Leukemia 1994, 8: 1224-1229
10. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991, 78: 1125-1131
11. Hongo T, Fujii Y, Yajima S. In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed chemotherapy. In: Kaspers et al. (eds). Drug Resistance in Leukemia and Lymphoma I. Harwood, 1993: 313-319
12. Klumper E, Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Rottier MMA, Van Wering ER, Van Der Does-van Den Berg A, Hählen K, Creutzig U, Veerman AJP. In vitro chemosensitivity testing in childhood acute non-lymphoblastic leukemia using the MTT assay. Leukemia 1995, 9: 1864-1869
13. Zwaan CM, Kaspers GJL, Rottier MMA, Wünsche R, Hählen K, Creuztig U, Pieters R, Veerman AJP. Circumvention of ARA-C resistance in childhood acute non-lymphoblastic leukemia (ANLL) by the use of 2chloro-deoxyadenosine: an in vitro study. Med Pediatr Oncol 1998, 31: 230 (abstract 0-144)
14. Kaspers GJL, Zwaan ChM, Creutzig U, Ritter J, Rottier MMA, Pieters R, Veerman AJP. In vitro drug resistance in childhood acute myeloid leukemia: A-preliminary analysis. In: Hiddemann et al. (eds). Acute Leukemias VII. Springer-Verlag, 1998: 491-495
15. Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE. Myeloperoxydase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood 1993, 81: 482-489
16. Schlaifer D, Meyer K, Muller C, Attal M, Smith MT, Tamaki S, Weimels J, Pris J, Jaffrezou JP, Laurent G, et al. Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. Leukemia 1994, 8: 289-291
17. Dübbers A, Schulze-Westhoff P, Kurzknabe E, Creutzig U, Ritter J, Boos J. Asparagine-synthetase in paediatric acute leukemias: AML-M5-subtype shows lowest activity. Ann Hematol 1997, 74 (suppl I): A37 (abstract #148)
18. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res 1997, 21: 45-50
19. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-betaD-arabinofuranosylcytosine in Down syndrome cells - a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996, 87: 3395-3403
20. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia 1997, 11: 1594-1595 [letter]
21. Zwaan CM, Ramakers-Van Woerden NL, Kaspers GJL, Pieters R, Wünsche R, Rottier MMA, Hählen K, Janka-Schaub G, Creutzig U, Veerman AJP. Favourable drug resistance profiles in children with Down's syndrome (DS) and acute leukemia. Br J Haematol 1998, 102: 226 (poster 904)
22. Dow LW, Dahl GV, Kalwinsky DK, Mirro J, Nash MB, Roberson PK. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 1986, 68: 400-405
23. Smith PJ, Lihou MG. Prediction of remission induction in childhood acute myeloid leukemia. Aust N Z J Med 1986, 16: 39-42
24. Rosanda C, Garaventa A, Pasino M, Strigini P, De Bernardi B. A short-term in vitro drug sensitivity assay in pediatric malignancies. Anticancer Res 1987, 7: 365-368
25. Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991, 338: 399-403
26. Kaspers GJL, AJP Veerman, R Pieters, Van Zantwijk CH, LA Smets, ER Van Wering, A Van Der Does-Van Den Berg. In vitro cellular drug resistance and prognosis in childhood acute lymphoblastic leukemia. Blood 1997, 90: 2723-2729
27. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJP. Prednisolone in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other anticancer agents. Blood 1998, 92: 259-266
28. Pieters R; Den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJL, Van Wering ER, veerman AJP. In vitro drug resistance testing in infant acute lymphoblastic leukemia cells - implications for treatment. Leukemia 1998, 12: 1344-1348
29. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leukemia & Lymphoma 1995, 19: 407-417
30. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 1995, 85: 751-756
31. Dörffel W, Hartmann R, Schober S, Veerman AJP, Pieters R, Klumper E, Henze G. Drug resistance testing as a basis for tailored therapy in children with refractory or relapsed acute lymphoblastic leukemia. In: Kaspers et al. (eds). Drug Resistance in Leukemia and Lymphoma I. Harwood, 1993: 353-357
32. Klumper E, Pieters R, Loonen AH, Huismans DR, Veerman AJP. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer 1995, 71: 1188-1193